Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis

Marina Serra Carrera, Macarena Simón-Talero, Desiree Campoy, Gonzalo Artaza, Mercedes Perez Lafuente, Sergi Camarillas, Sofia Laura Muzio, Jonay Mendez, Maria Landwehr, Francesc Bosch, Pável E Olivera

Blood (2024) 144 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2024-209784

Published: 2024

Journal Articles

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Sofia Muzio, Gonzalo Artaza, Olga Benitez Hidalgo, Vicente Cortina, Desiree Campoy, Francisco Beas, Marc Bosch, Marina Serra, Francesc Bosch, Pável E Olivera

Blood (2023) 142 (Supplement 1): 4019.

https://doi.org/10.1182/blood-2023-190604

Published: 2023

Journal Articles

Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy

Desiree Campoy, MD, Katia Flores, MD, Gonzalo Artaza, MD, César A Velasquez, MD, Tania Canals, MD, Erik A Johansson, MD, Agustí Peró, MD, Jorge Sierra, MD, Ramón Salinas, MD PhD, Pável E Olivera, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-141908

Published: 2020

Journal Articles

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Pável E Olivera, MD, César A Velasquez, MD, Desirée Campoy, MD, Gonzalo Artaza, MD, Tania Canals, MD, Katia Flores, MD, Silvia Ruiz, MD, Alessandra Comai, MD, Erik A Johansson, MD, Gabriela S Ene, MD PhD, Gabriela Bastidas, MD, Maricel Subira, MD PhD, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 3661.

https://doi.org/10.1182/blood-2019-128300

Published: 2019

Journal Articles

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Desirée Campoy, MD, Gonzalo Artaza, MD, César A Velasquez, MD, Tania Canals, MD, Erik A Johansson, MD, Katia Flores, MD, Gabriela Bastidas, MD, Silvia Ruiz, MD, Gabriela S Ene, MD PhD, Alessandra Comai, MD, Maricel Subira, MD PhD, Ramón Salinas, MD PhD, Jorge Sierra, MD, Pável E Olivera, MD

Blood (2019) 134 (Supplement_1): 1162.

https://doi.org/10.1182/blood-2019-125150

Published: 2019

Journal Articles

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Pável E Olivera, MD, Desirée Campoy, MD, César A Velasquez, MD, Katia Flores, MD, Gabriela S Ene, MD PhD, Tania Canals, MD, Gonzalo Artaza, MD, Maricel Subira, MD, Sofía Vila, Undergraduate student, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2018) 132 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2018-99-119114

Published: 2018

NARROW

Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Email alerts

ASH Publications

American Society of Hematology

Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only